avapritinib
blueprint medicines
['sarcoma', '#gi', 'avapritinib']
outcomes from the largest single center european #pdgfra mutant #gist cohort. all 3 patients who received #avapritinib showed objective response and 2 patients remain on avapritnib at 26 months &amp; 7 months. #sarcoma #asco22 
Enhancing survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts.